BIOMAT Database Logo BIOMAT Database Logo

Effects of inhaled nitric oxide in rats with chemically induced pulmonary hypertension. 1994

Y Katayama, and K Hatanaka, and T Hayashi, and K Onoda, and I Yada, and S Namikawa, and H Yuasa, and M Kusagawa, and K Maruyama, and M Kitabatake
Department of Thoracic and Cardiovascular Surgery, Mie University of School of Medicine, Japan.

To determine the model animal with pulmonary hypertension in which nitric oxide (NO) inhalation reduces pulmonary arterial pressure (PAP), we examined the inhalation of 20-100 ppm NO gas on normal rats and rats with monocrotaline induced pulmonary hypertension. In the control group, mean PAP showed no change after spontaneous breathing of NO at the concentration of 20 to 100 ppm for 5 min. On the contrary, in both the severe (mean PAP > 40 mmHg) and moderate (mean PAP < 40 mmHg) pulmonary hypertensive groups, NO inhalation produced a prompt reduction of the mean PAP which had been elevated by monocrotaline. 20 ppm NO inhalation reduced mean PAP from 64.4 +/- 3.7 mmHg to 56.2 +/- 4.4 mmHg (mean +/- SEM, P < 0.01) in the severe pulmonary hypertensive group, from 31.0 +/- 2.0 mmHg to 24.2 +/- 0.9 mmHg in the moderate pulmonary hypertensive group (mean +/- SEM, P < 0.05). The onset of the reduction of mean PAP occurred within 30 sec after the start of NO inhalation and maximum reduction occurred within 4 min. 20 ppm NO inhalation significantly reduced mean PAP, and mean PAP was reduced dose-dependently at the concentration of 20 to 60 ppm and reaction to NO was almost constant at the concentrations of over 60 ppm.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008297 Male Males
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D011651 Pulmonary Artery The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. Arteries, Pulmonary,Artery, Pulmonary,Pulmonary Arteries
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016686 Monocrotaline A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment. Monocrotaline Hydrochloride (13alpha,14alpha)-Isomer,Monocrotaline, (all-xi)-Isomer
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Y Katayama, and K Hatanaka, and T Hayashi, and K Onoda, and I Yada, and S Namikawa, and H Yuasa, and M Kusagawa, and K Maruyama, and M Kitabatake
[Hemodynamic effects of inhaled nitric oxide in patients with pulmonary hypertension].
May 1995, Zhonghua yi xue za zhi,
Y Katayama, and K Hatanaka, and T Hayashi, and K Onoda, and I Yada, and S Namikawa, and H Yuasa, and M Kusagawa, and K Maruyama, and M Kitabatake
Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension.
March 2024, Clinics in perinatology,
Y Katayama, and K Hatanaka, and T Hayashi, and K Onoda, and I Yada, and S Namikawa, and H Yuasa, and M Kusagawa, and K Maruyama, and M Kitabatake
Pulmonary vascular effects of pulsed inhaled nitric oxide in COPD patients with pulmonary hypertension.
January 2016, International journal of chronic obstructive pulmonary disease,
Y Katayama, and K Hatanaka, and T Hayashi, and K Onoda, and I Yada, and S Namikawa, and H Yuasa, and M Kusagawa, and K Maruyama, and M Kitabatake
Effects of inhaled nitric oxide on platelet-activating factor-induced pulmonary hypertension in dogs.
March 1998, Acta anaesthesiologica Scandinavica,
Y Katayama, and K Hatanaka, and T Hayashi, and K Onoda, and I Yada, and S Namikawa, and H Yuasa, and M Kusagawa, and K Maruyama, and M Kitabatake
Inhaled nitric oxide in neonates with persistent pulmonary hypertension.
January 2001, Lancet (London, England),
Y Katayama, and K Hatanaka, and T Hayashi, and K Onoda, and I Yada, and S Namikawa, and H Yuasa, and M Kusagawa, and K Maruyama, and M Kitabatake
Effect of inhaled nitric oxide in endothelin-1-induced pulmonary hypertension.
January 1998, Biology of the neonate,
Y Katayama, and K Hatanaka, and T Hayashi, and K Onoda, and I Yada, and S Namikawa, and H Yuasa, and M Kusagawa, and K Maruyama, and M Kitabatake
Treatment of acute pulmonary hypertension with inhaled nitric oxide.
October 1994, The Annals of thoracic surgery,
Y Katayama, and K Hatanaka, and T Hayashi, and K Onoda, and I Yada, and S Namikawa, and H Yuasa, and M Kusagawa, and K Maruyama, and M Kitabatake
Inhaled nitric oxide versus prostacyclin in chronic shunt-induced pulmonary hypertension.
November 2003, The Journal of thoracic and cardiovascular surgery,
Y Katayama, and K Hatanaka, and T Hayashi, and K Onoda, and I Yada, and S Namikawa, and H Yuasa, and M Kusagawa, and K Maruyama, and M Kitabatake
In pigs, inhaled nitric oxide (NO) counterbalances PAF-induced pulmonary hypertension.
November 1994, Prostaglandins, leukotrienes, and essential fatty acids,
Y Katayama, and K Hatanaka, and T Hayashi, and K Onoda, and I Yada, and S Namikawa, and H Yuasa, and M Kusagawa, and K Maruyama, and M Kitabatake
Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension.
November 1998, American journal of respiratory and critical care medicine,
Copied contents to your clipboard!